G&E Herbal Biotechnology Co., Ltd.

About G&E Herbal Biotechnology Co., Ltd.

G&E Herbal Biotechnology Co., Ltd., a biotechnology company, focuses on the development and commercialization of novel botanical extraction technology and products in Taiwan. It offers hepato protective agent capsules for the treatment of chronic liver inflammation, cirrhosis, hepatitis, and other liver diseases; botanical anti-aging cosmetic products; and SR-100 skin repair gel. The company also provides botanical healthcare products, such as Astragali Radix for physical strength; Goji for eyes; and Prosta capsule for regulating physiological functions and boosting metabolism, as well as offers adult products. In addition, it is developing Solarise injection for the treatment of gynecological, head, and neck cancer; Apocin capsule for the treatment of lung/breast cancer; and SR-T100 Gel. Further, the company manufactures technology development for various dietary supplements, as well as provides technical advisory services to other biotechnology organizations. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.

德英生物科技股份有限公司為台灣上市櫃公司(股票代號4911),係專業之植物新藥開發公司,創立於2002年,主要生產植物藥相關藥品、保健食品及保養品。

https://www.geherbs.com.tw

4911.TWO Taiwan

62.9USD0.4 (+0.64%)

• At close Thu Oct 06 2022

Taipei Exchange exchange

Sector: Healthcare

Industry: Biotechnology

Location Taiwan, Tainan City

Grade: ADF

140,753,175 USD
MARKET CAP
555.000
PE
0.160
BETA (5y)
0.140
EPS

Profits

for 5 years
23%
for 3 years
70%
for 2 years
107%
for last year
127%
for this year
0%
G&E Herbal Biotechnology Co., Ltd.
© 2024 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.